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Abstract 
We demonstrate the first true real-time in vivo video imaging of extracellular protease ex-
pression using an ultrafast-acting and extended-use activatable probe. This simple, one-step 
technique is capable of boosting fluorescent signals upon target protease cleavage as early as 
30 minutes from injection in a small animal model and is able to sustain the strong fluorescent 
signal up to 24 hours. Using this method, we video imaged the expression and inhibition of 
matrix metalloproteinases (MMPs) in a tumor-bearing mouse model. The current platform 
can be universally applied to any target protease of interest with a known peptide substrate 
and is adaptable to a wide range of real-time imaging applications with high throughputs such 
as for in vivo drug screening, examinations of the therapeutic efficacy of drugs, and monitoring 
of disease onset and development in animal models. 
Key words: matrix metalloproteinases (MMPs), activatable probes, near-infrared fluorescence im-
aging, real-time in vivo video imaging, peptide substrate, PEGylation. 
Introduction 
Most new drug candidates generated during in 
vitro  screening  turn  out  to  be  invalid  after 
time-consuming and costly testing in animal models. 
Therefore, there is an urgent need for development of 
noninvasive,  real-time,  sensitive,  and  cost-effective 
tools with high throughput for monitoring and early 
detection of drug efficacy in vivo. Optical molecular 
imaging  provides  many  advantages  over  other  im-
aging modalities, including high sensitivity and safe 
detection with non-radioactive materials, using read-
ily available instruments, at moderate cost [1]. Further 
improvements in performance of in vivo optical im-
aging are dependent on the development of sophisti-
cated imaging probes that exhibit high sensitivity and 
low  background  noise.  Among  the  diverse  applica-
tions,  peptide-based  molecular  beacons,  so  called 
protease activatable optical  probes, have enabled  in 
vivo  imaging  of  protease  activity  and  demonstrated 
promising results in the field of protease research and 
protease-targeted drug development [2-3]. 
Proteases  are  known  as  exceptionally  critical 
signaling  proteins  that  are  involved  in  numerous 
processes,  such  as  inflammation,  as  well  as  cancer, 
neurological  disorders,  and  cardiovascular  diseases 
[4].  It  is  of  no  surprise,  therefore,  that  several 
small-molecule inhibitors targeting proteases are al-Theranostics 2011, 1 
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ready on the market, and a significant number of new 
therapies based on protease inhibition are under vig-
orous  clinical  investigation.  The  unique  differential 
expression of proteases in diseases enable particular 
types of protease to be used as a specific biomarkers 
for  diagnosis  and  as  target  molecules  for  prote-
ase-activated prodrugs [5]. Considerable efforts have 
been made to identify the role of certain proteases in 
given biological processes and to screen specific mol-
ecules  that  can  regulate  protease  expression.  Most 
experimental methods are based on the use of prote-
ase  reporters  or  molecular  beacons.  Moreover,  they 
are limited to in vitro applications.  
With  the  development  of  hydrophilic 
near-infrared  (NIR)  dyes  and  quenchers,  it  is  now 
possible  to  use  conventional  molecular  beacon  con-
structs as in vivo imaging agents [6-7]. These probes 
are optically silent (quenched) in their native state and 
are  activated  in  the  presence  of  a  specific  protease, 
thereby  generating  an  NIR  fluorescence  signal. 
However, the inherent instability, short half-life, and 
nonspecific  activation  of  peptides  and  small  com-
pounds are still major obstacles to their in vivo appli-
cation  by  systemic  administration.  Conjugation  of 
macromolecules,  such  as  high  molecular  weight 
poly(amino  acids)  and  poly(ethylene)  glycol  (PEG), 
efficiently  increases  the  in vivo  stability  [8],  but  de-
creases the sensitivity  and specificity  of the probes. 
This  is  because  conjugated  macromolecules  require 
longer circulation times to produce high contrast im-
ages through accumulation at tumor sites by the en-
hanced permeability and retention effect (EPR), and a 
consequence can be non-specific signal activation by 
proteases  present  in  the  blood.  For  example,  com-
mercially  available  VisEn’s  protease  activatable 
probes  targeting  matrix  metalloproteinases  (MMPs) 
(MMPSense™, VisEn, Bedford, MA, USA) have been 
widely used [9]. However, the probes typically take a 
long time (~ 24 hr) to be fully activated in vitro and in 
vivo,  which  may  be  due  to  their  conjugated, 
high-molecular-weight  polymer  backbone.  Delayed 
activation hampers real-time and high-throughput in 
vivo applications. Therefore, it is important to strike a 
balance between stability and sensitivity of the probes 
in vivo to enable  quick screening and true real-time 
imaging  of  enzyme  activity  in  live  animals,  and  to 
achieve  superior  target-to-background  contrast.  Re-
cently, we and others have developed various novel 
activatable  imaging  probes  that  can  provide 
high-resolution imaging and low background signals 
[3, 10-13]. Although these reported systems are sensi-
tive, they have limited applications due to the modest 
and delayed fluorescent changes of the probes, thus 
allowing  only  snap-shot  in vivo  images,  rather  than 
real-time video images of the whole-body. 
In  this  study,  we  present  a  simple  method  to 
upgrade  a  conventional  molecular  beacon  to  an  ul-
trafast-acting and extended-use activatable probe. We 
found that the PEGylation of a molecular beacon with 
a specific size PEG can significantly alter the activa-
tion  properties  of  the  probe  and  permit  real-time 
video  imaging  of  protease  expression  in  vivo.  We 
chose MMPs as our initial target proteases. MMPs are 
a family of zinc-dependent endopeptidases and rep-
resent the most well-known proteases associated with 
tumorigenesis [14]. 
2. Materials and Methods 
Cell culture and animal models. Squamous cell 
carcinoma  SCC-7  were  cultured  in  RPMI  1640  me-
dium containing 10% (v/v) fetal bovine serum (Invi-
trogen) supplemented with penicillin (100 g/ml) and 
streptomycin  (100  g/ml)  at  37  C  with  5%  CO2. 
SCC-7 tumor model was developed by subcutaneous 
injection of 1×106 cells into the right front flank of fe-
male athymic nude mice (Harlan Laboratories). The 
mice were used for optical studies when the tumor 
volume reached about 300 mm3. All animal studies 
were conducted in accordance with the principles and 
procedures outlined in the NRC Guide for the Care 
and Use of Laboratory Animals and were approved 
by the Institutional Animal Care and Use Committee 
of the Clinical Center, NIH. 
Synthesis  of  the  MMP-Pns.  MMP-Pn  is  com-
posed of i) Cy5.5 as a NIR dye (ex/em: 675/695 nm), 
ii)  MMP  substrate  GPLGVRGKGG  as  a  recognition 
site indicated by italics with the cleavage site between 
Gly and Val, iii) Cy5.5 quencher BHQ-3 (maximum 
abs. 650 nm), and iv) PEG as a backbone. The peptide 
sequence  was  synthesized  by  standard  solid-phase 
Fmoc  peptide  chemistry.  MMP-Pn  was  synthesized 
through serial conjugation and deprotection of pep-
tide  in  solution  followed  by  preparative  re-
versed-phase  high-performance  liquid  chromatog-
raphy  (RP-HPLC)  purifications.  The  final  products 
were confirmed by analytical RP-HPLC and LC-mass 
spectroscopy.  Cy5.5-NHS  was  purchased  from  GE 
Healthcare  (Piscataway,  NJ)  and  BHQ-3  NHS  ester 
was  obtained  from  Biosearch  Technology  (Navato, 
CA).  Amino  PEG  analogs  NH2-R1  were  purchased 
from  Quanta  Biodesign  (Powell,  OH)  and  Sig-
ma-Aldrich (St-Louis, MO). All other chemicals were 
of  analytical  grade  and  were  purchased  from  Sig-
ma-Aldrich.  
In  vitro  enzyme  test.  The  activity  of  the 
MMP-Pns was investigated in vitro by incubating the 
probe (15 nM) in the reaction buffer (50 mM Tris·HCl, Theranostics 2011, 1 
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10 mM CaCl2·2H2O, 0.15 M NaCl, 0.05% Brij35, pH 
7.8, TCNB buffer) containing an appropriate amount 
of activated MMPs. Recombinant human MMPs were 
activated with 2.5 mM p-aminophenylmercuric ace-
tate (APMA) in the reaction buffer for 1 to 2 hrs at 37 
C  before  use.  A  homophenylalanine-hydroxamin 
acid  based  broad-spectrum  MMP  inhibitor  MMP-I 
(MMP  Inhibitor  III,  Merck  KGaA,  Darmstadt,  Ger-
many) was used for  the  MMP inhibition test.  Fluo-
rescence intensity was monitored using a spectroflu-
orometer  equipped  with  micro-well  plate  reader 
(F-7000  Fluorescence  Spectrophotometer,  Hitach, 
Tokyo, Japan) every 10 min at 37 °C. The excitation 
wavelength was set at 675 nm and emission spectra 
were recorded from 680 to 800 nm.  
In vivo imaging. Optical image aquisition and 
analysis were done using a Maestro 2 imaging system 
(Cri, Woburn, MA, USA). The MMP-Pns (100  L in 
PBS pH 7.4, 300 nM) and MMPSense 680™ (150 L, as 
recommended by the manufacturer, VisEn, Bedford, 
MA, USA) were injected via tail vein. Imaging was 
performed for 24 hrs using Maestro 2 configured for 
Cy5.5 detection at the indicated time points after the 
injection of the probes. For video imaging, 100 L of 
the MMP-P12 was injected via tail vein catheter and 
imaging was  performed every 10 sec for the first 5 
min, 15 sec for 5 to 30 min, and 20 sec for 30 to 60 min, 
respectively, using Maestro’s DyCE function. To in-
hibit the MMP activity, the MMP-I (1 mM) was in-
jected intratumorally 30 min before the  intravenous 
injection of the probe. Images were normalized and 
analyzed by using Maestro software. For quantitative 
comparison, the regions of interest (ROI) were drawn 
over tumor (T) and normal tissue (N, muscle), and the 
average signal (×106 photons×cm-2×s-1) for each area 
was measured. Results were presented as means  s.d. 
for a group of 3-6 animals. 
Ex vivo biodistribution. At 4 h after injection of 
the probes, mice were sacrificed and tumors and ma-
jor organs were carefully excised and rinsed with sa-
line. Excised samples were immediately imaged and 
analyzed by using Maestro 2. Results were presented 
as means  s.d. for a group of 3 animals. 
Histological analysis. Excised tumor tissue slic-
es (4 m) were fixed with cold acetone for 20 min and 
dried  in  air  for  30  min  at  room  temperature.  After 
blocking with 10% BSA for 30 min, the sections were 
incubated with Rabbit anti-MMP-2, -9 and MMP-13 
antibodies (10 g/mL) for 60 min at room tempera-
ture  in  the  dark,  and  then  visualized  with 
FITC-conjugated  donkey  anti-rabbit  secondary  anti-
body.  Finally,  the  slices  were  mounted  with 
DAPI-containing  mounting  medium  under  an 
epifluorescence microscope (Olympus, X81). For NIR 
fluorescence  imaging,  tumor  slices  were  viewed  by 
fluorescence microscopy equipped with a Cy5.5 filter.  
3. Results and Discussion 
We hypothesized that PEGylation of molecular 
beacons by PEGs of different size would induce dif-
ferent  probe  specificity  and  sensitivity  effects,  since 
PEG can alter the stability, half-life, and enzyme sus-
ceptibility of the probe dependent on the steric hin-
drance and molecular weight (MW) of the PEG [15]. 
In this study, we found that the addition of small MW 
PEG as a backbone to a fluorescently-quenched mo-
lecular beacon can significantly alter the beacon’s ac-
tivation profiles under physiological conditions. We 
synthesized a series of PEGylated molecular beacons, 
screened  their  activity  in  vitro  and  in  vivo,  and  as-
sessed their suitability for video imaging of protease 
expression in an MMP-overexpressing tumor-bearing 
mouse model. We began by preparing MMP activat-
able  molecular  beacons  without  a  PEG  backbone, 
termed MMP-P0.. The MMP-P0 consisted of Cy5.5 and 
BHQ-3  as  a  near-infrared  dye/dark  quencher  pair, 
Cy5.5-GPLGVRGK(BHQ-3)GG[10].  Next,  PEGs  of 
different sizes were conjugated to the C-termini of the 
MMP-P0 (MMP-Pn, where “n” represents the number 
of repeating ethylene glycol units, –CH2CH2O-) (Ta-
ble 1 and Fig. 1). MMP-13 was used as a model MMP 
for in vitro screening since MMP-P0 showed highest 
specificity against MMP-13 (Fig. 2a). The activity of 
each MMP-Pn (n = 0, 4, 12, 24, and 67) was tested by 
incubating 15 nM of each probe in a 96-well micro-
plate containing the reaction buffer and 40 nM of ac-
tivated MMP-13, with and without a broad spectrum 
hydroxamate-type MMP inhibitor (MMP-I). Fluores-
cence  spectrometry  clearly  demonstrated  that 
MMP-Pns can be significantly and fully activated (> 
25-fold vs. without MMP) in the presence of MMP-13 
within  an  hour  (Fig.  2b  and  Fig.  2c).  All  MMP-Pns 
showed  a  linear  relationship  between  the  activated 
fluorescent signals and MMP-13 concentrations and 
were able to detect nanomolar concentrations of en-
zyme  (Fig.  2d).  The  rate  of  activation  was  slightly 
enhanced for MMP-P12, which may be due to the im-
proved solubility of the probe by PEG, but decreased 
when higher MW PEG was conjugated because of a 
steric-hindrance  effect.  However,  no  significant  dif-
ferences among the MMP-Pns  were observed  under 
the tested in vitro conditions. 
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Table 1. Chemical structures of the MMP-Pns. Molecular weight (MW) of the MMP-P0 is 2324.95. 
 
 
 
 
 
 
 
Figure  1.  (a)  Synthesis  of  the  MMP-Pns.  Reagents:  a)  HSPyU,  2%  DIPEA/DMF,  NH2-R1;  b)  20%  piperdine/DMF;  c) 
Cy5.5-NHS ester, 2% DIPEA/DMF; d) TFA/water/TIS (95/2.5/2.5, v/v/v); e) BHQ-3 NHS ester, 2% DIPEA/DMF.  Theranostics 2011, 1 
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Figure 2. (a) Recovery of fluorescence of the MMP-P0 (15 nM) in the presence of various activated MMPs (40 nmol/L) 
following 80 min incubation at 37 C. (b, c) Fluorescence activation of the MMP-Ps (20 nM) in a solution containing activated 
MMP-13 (40 nmol/L) following 80 min incubation at 37 C. (b) Fluorescence emission spectra of the MMP-Ps before 
(quenched state, low fluorescence intensity, signals enlarged in inset) and after (activated state, increased fluorescence 
intensity) addition of activated MMP-13. (c) Fluorescence emission kinetic spectra of the activated MMP-Ps in the presence 
of MMP-13 with and without a broad spectrum MMP inhibitor (MMP-I). (d) Fluorescence intensities of the MMP-Pns in the 
presence of various concentrations of activated MMP-13 (1, 2, 5, 10, 20, and 40 nM) following a 20 min incubation. Means ± 
s.d. (n = 3). 
 
 
To  evaluate  whether  a  particular  type  of 
MMP-Pn  can  improve  the  visualization  of  overex-
pressed MMPs in vivo, the MMP-Pns and MMPSense 
680™ were administered intravenously into separate 
MMP-positive  SCC-7  tumor-bearing  mice.  In  vivo 
imaging  was  performed  for  24  hrs  using  a 
small-animal  imaging  system  (Maestro  2,  Cri,  Wo-
burn,  MA,  USA).  Surprisingly,  modification  of 
MMP-Pn  with  small  MW  PEG  showed  significantly 
reduced activation time (ultrafast-acting and extend-
ed-use) in vivo. Fig. 3 shows representative serial im-
ages of mice at selected time points. In contrast to the 
in vitro activity, MMP-P4 and MMP-P12 clearly showed 
early  onset  of  activation  in vivo  and  provided  high 
NIR fluorescence signals in the MMP-positive tumor 
region for a longer time compared to other MMP-Pns 
and MMPSense 680™. The activation of fluorescence 
signals in the tumor region was enhanced when the 
MW of the PEG backbone was increased up to 500 Da 
and  gradually  decreased  with  further  increases  of 
PEG MW. MMPSense 680™ showed a slightly posi-
tive fluorescent signal in the tumor region 24 hrs post 
injection (Fig. 4), however, the normalized signal was 
significantly  lower  than  all  MMP-Pns,  except  for 
MMP-P48. The ratio of the signal in the regions of in-
terest (ROI) in the tumor compared to the normal re-
gion (T/N) of MMP-P12 was up to 3-fold higher than 
any other tested compounds at any time point (Fig. 
5a).  The  biodistributions  of  MMP-P0,  MMP-P12  and 
MMPSense 680™ were evaluated ex vivo after careful Theranostics 2011, 1 
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removal of tumors and other organs, after in vivo im-
aging, at 4 hrs post injection. As shown in Fig.  5b, 
MMP-P12 was activated predominantly in the tumors. 
Tumor sections were also analyzed. Fluorescence mi-
croscopy  showed  strong  fluorescence  signal  con-
sistent with in vivo imaging and anti-MMP antibody 
staining (for MMP-2, 9, 13), revealing strong expres-
sion of MMPs in SCC7 tumors (Fig. 5c and Fig. 6). 
These results indicate that molecular beacon targeting 
of specific proteases can be tested efficiently and op-
timized by simple small-MW PEG bioconjugation for 
in vivo applications in disease models. 
 
 
Figure 3. Whole-mouse imaging with Maestro 2 (CRI). (a) Representative serial fluorescence images of MMPs-positive 
SCC7 tumor-bearing mice injected intravenously with the MMP-Ps and MMPSense 680™. Images were acquired at the 
indicated time points and were normalized by the maximum average value. The color bar indicates radiant efficiency (low, 0; 
high, 2.62×10
5). Theranostics 2011, 1 
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Figure  4.  Representative  serial  fluorescence  images  of 
MMP-positive SCC7 tumor bearing mice injected intravenously 
with 150 L of MMPSense 680™ (2 nmol). The color bar indi-
cates radiant efficiency (low, 0; high, 4.7×10
4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  5.  (a)  Region  of  interest  (ROI)  tu-
mor-to-normal  tissue  (T/N)  ratio  analysis  of  fluo-
rescence intensity of SCC7 tumor in vivo. (b) Biodis-
tribution  of  the  MMP-P0,  MMP-P12  and  MMPSense 
680™ 4 h post-injection. (c) NIR fluorescence mi-
croscopy  of  SCC7  tumor  injected  with  MMP-P12 
(left),  tumor  section  counterstained  with  primary 
antibody  for  MMP-13  (middle)  and  their  merged 
images (right). Means ± s.d. (n = 3-6/group). *P < 0.05 
(Student’s  t-test)  for  MMP-P12  relative  to  other 
probes.  
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Figure 6. (a) Immunohistochemistry of MMP expression in a SCC7 tumor section counterstained with primary antibodies 
for MMP-2, 9, and 13, respectively. (b) NIR fluorescence microscopy of SCC7 tumor injected with MMP-P0 and MMP-P12. 
The slices were mounted with DAPI-containing mounting medium and examined under an epifluorescence microscope using 
Cy5.5 filter (Olympus X81). Original magnification was ×200. Exposure time: 1 sec. 
 
 
After systemic validation of MMP-Pns, we inves-
tigated whether we could video image the activity of 
MMPs  in  vivo.  To  inhibit  the  activity  of  MMPs  in 
SCC-7 tumor-bearing  mice, MMP-I was intratumor-
ally  injected  30  min  before  the  probe  injection. 
MMP-P12 was injected into mice either directly or fol-
lowing  MMP-I  treatment,  using  a  tail  vein  catheter 
during continuous imaging procedures. The animals 
were imaged every 10 to 20 sec for 1 hr and video 
images  were  generated  by  using  imaging  software 
(DyCE, Cri, Woburn, MA, USA). Fig. 7a shows a typ-
ical series of video images. The MMP-P12 generated 
strong NIR fluorescence signals as early as 20 to 30 
min after the probe injection and enabled clear visu-
alization  of  MMPs  in  the  tumor  region  thereafter 
(Supplementary Video 1). In contrast, the overall NIR 
fluorescent signals were significantly decreased when 
the  activity  of  MMPs  was  suppressed  by  the  MMP 
inhibitor (Supplementary Video 2). The mean fluo-
rescent intensity of the tumor ROI and the T/N ratios 
analyzed  from  normalized  snapshot  images  clearly 
confirm  that  the  fluorescent  activation  of  MMP-P12 
can  be  inhibited  significantly  in  the  presence  of 
MMP-I (Fig. 7b and Fig. 8). These results demonstrate 
the possibility of using our probe to monitor expres-
sion and inhibition of MMPs in vivo in real-time. 
In summary, we’ve presented a screening plat-
form of activatable imaging probes to target extracel-
lular  proteases  of  interest  in vivo.  Any  known  pep-
tide-based molecular beacon construct designed for in 
vitro  application  could  be  successfully  tuned  to  be-
come  an  in  vivo  imaging  probe  to  visualize  target 
proteases  non-invasively  and  spatiotemporally  in  a 
rapid and efficient fashion. Optimized probes can be 
applied to a wide array of in vivo applications, such as 
drug screening with higher throughput, examinations 
of therapeutic efficacy, and monitoring of disease on-
set  and  development  in  animal  models.  The  ad-
vantages  over  protease  reporters  or  other  poly-
mer-based agents, are greater flexibility and tunabil-
ity, and easier synthesis, scale-up, and handling. In 
this study, we did not attempt to quantify protease 
expression. We anticipate that current development of 
a  real-time  quantitative  imaging  system  using  ad-
vanced imaging software algorithms will improve the 
capabilities of our probes in the near future.  
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Figure 7. (a) Real-time video imaging of MMP expression in SCC7 tumor-bearing mice. MMP-P12 was injected into mice with 
or without MMP-I treatment via tail vein catheter during the imaging procedures. Whole-mouse images were obtained every 
10 to 20 sec for 1 hr. Images were normalized by the maximum average value. The color bar indicates radiant efficiency (low, 
0; high, 4.8×10
4). (b) ROI analysis of fluorescence intensity in tumor. The original video images (Supplemental Video 1 and 
Supplemental Video 2) are presented in the Supplemental Information. Means  s.d. (n = 3). *P < 0.05 (Student’s t-test).  
 
Figure 8. ROI T/N ratio analysis of fluorescence intensity in SCC7 tumor with or without MMP-I. Means  s.d. (n = 3). *P 
< 0.05 (Student’s t-test). 
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Supplementary Video 1 
[http://www.thno.org/v01p0018s1.avi] 
Supplementary Video 2    
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